Clinical Updates on PSMA-PET Imaging for Prostate Cancer

In this introductory dialogue, Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss PSMA-PET's transformative role alongside conventional techniques in prostate cancer imaging.

Experts explore PSMA's significance in prostate cancer imaging, covering its expression, limitations, and transformative role in detecting even low PSA recurrences with PSMA-PET technology.

Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, delve into patient selection for PSMA PET CT scans, discussing indications spanning initial diagnosis and recurrence, as well as institution guidelines.

Shared insight into FDA-approved PSMA PET imaging tracers, highlighting similarities and differences between gallium 68 and fluorine 18 compounds.

A review of available PSMA PET tracers for prostate cancer detection, covering sensitivity, specificity, access to therapy, and reimbursement impacting patient care.

Key opinion leaders discuss how PSMA PET CT tracers, including gallium 68 and fluorine 18, are revolutionizing prostate cancer patient management and with accurate and early detection of disease spread.

Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss the consensus between clinical guidelines for PSMA PET CT usage in prostate cancer, emphasizing multidisciplinary collaboration and the importance of urologists' involvement.

Factors impacting the choice between gallium 68 and fluorine 18 PSMA PET tracers, including half-lives, institutional capabilities, access to resources, detection rates, reimbursement constraints, and potential differences in interpretation.

Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.